Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05687799
Other study ID # 2022/108
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 22, 2022
Est. completion date March 22, 2023

Study information

Verified date April 2023
Source Nigde Omer Halisdemir University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Parkinson's Disease (PD) is a neurodegenerative disease characterized by chronic and progressive loss of dopaminergic neurons in the substantia nigra (SN) pars compacta. Sleep disturbances and fatigue are very common problems in Parkinson's patients. He reported that the frequency of fatigue was 47% in patients with a disease duration of less than five years and 70% in patients with a disease duration of more than five years. Fatigue in PD has been found to be associated with decreased physical activity, decreased functionality, sleep disorders, gait disturbances, motor findings, autonomic findings, increased levodopa dose, and motor fluctuations. Motor and non-motor symptoms in Parkinson's patients affect the individual's ability to perform activities of daily living independently. Impairments in functional status lead to negative consequences on quality of life. PD affects the individual not only physically, but also psychologically and socially.The neutrophil/lymphocyte ratio is a marker of peripheral inflammation. The relationship of peripheral inflammation to quality of sleep, quality of life and fatigue in individuals is unclear. The aim of this study was to investigation fatigue, quality of sleep and quality of life, and the relationship between neutrophil/lymphocyte ratio in Parkinson's patients.


Description:

Parkinson's Disease (PD) is a neurodegenerative disease characterized by chronic and progressive loss of dopaminergic neurons in the substantia nigra (SN) pars compacta. Sleep disturbances and fatigue are very common problems in Parkinson's patients. He reported that the frequency of fatigue was 47% in patients with a disease duration of less than five years and 70% in patients with a disease duration of more than five years. Fatigue in PD has been found to be associated with decreased physical activity, decreased functionality, sleep disorders, gait disturbances, motor findings, autonomic findings, increased levodopa dose, and motor fluctuations. Motor and non-motor symptoms in Parkinson's patients affect the individual's ability to perform activities of daily living independently. Impairments in functional status lead to negative consequences on quality of life. PD affects the individual not only physically, but also psychologically and socially.The neutrophil/lymphocyte ratio is a marker of peripheral inflammation. The relationship of peripheral inflammation to quality of sleep, quality of life and fatigue in individuals is unclear. The aim of this study was to investigation fatigue, quality of sleep and quality of life, and the relationship between neutrophil/lymphocyte ratio in Parkinson's patients.The aim of this study was to investigation fatigue, quality of sleep and quality of life, and the relationship between neutrophil/lymphocyte ratio in Parkinson's patients. A total of 39 Parkinson's Disease age of older the 50 participate in the research.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date March 22, 2023
Est. primary completion date March 22, 2023
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Being diagnosed with idiopathic Parkinson's disease - Healthy individuals who do not have musculoskeletal disease or any neurological disease that may affect assessments - Older than 50 years old - Volunteer to participate in the study - Grade 1-3 on the Modified Hoehn-Yahr Scale - To have a score above 24 in the Standardized Mini Mental Test - To have a hemogram follow-up in the last 1 month before the date of participation in the study. - Being able to walk independently on flat ground Exclusion Criteria: - Having an additional or psychiatric disease other than Parkinson's disease - Lack of cooperation - Presence of orthopedic problems (such as fractures, osteoporosis, osteomyelitis)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Nigde Omer Halisdemir University Treaning and Research Hospital Nigde

Sponsors (1)

Lead Sponsor Collaborator
Nigde Omer Halisdemir University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Other Standardized Mini Mental Test There are 19 items in this test, which consists of 5 main parts: orientation, recording memory, attention and calculation, recall and language. The total score of the test is evaluated out of 30 and 24 points are accepted as the threshold value for the diagnosis of mild dementia. The higher the score, the higher the cognition of individuals. Baseline
Primary Parkinson's Disease Quality of Life-8 One question from each of the eight domains in Parkinson's Disease Quality of Life-39, which are activities of daily living, physical discomfort, cognition, communication, emotional well-being, mobility, social support and stigma, gives the total domain score.Each question is scored between 0-4 points and points are added up. The total score is then divided by the total possible score and given as a percentage point out of 100. The lower the score, the higher the quality of life. Baseline
Primary Hemogram The neutrophil/lymphocyte ratio is a marker of peripheral inflammation. Baseline
Primary Parkinson's Fatigue Scale-16 The scale is the only fatigue scale specific to PD developed by Brown et al. It examines the impact of fatigue on daily life and consists of 16 items designed to assess the physical effects of fatigue. The scale allows to measure the presence of fatigue (seven items) and its effect on daily function (nine items). The subjects are asked to respond to the statements about fatigue between 1 (strongly disagree) and 5 (strongly agree). The higher score, the worsen fatigue scale in participant. Baseline
Primary The Parkinson's Disease Sleep Scale Parkinson's Disease Sleep Scale consists of 15 questions to be answered by the patient. With this, the quality of sleep as a whole during the night, difficulty in starting and maintaining sleep, night restlessness, nocturnal psychosis, nocturia, nocturnal motor symptoms, restlessness of sleep and naps during the day can be evaluated. The test is done by giving a score between 0 (very severe complaints) and 10 (no complaints) for each question. The total score point is 150. Higher scores indicate better sleep quality. Baseline
Secondary Unified Parkinson's Disease Rating Scale This scale was created to evaluate the motor performance, mental and mental status, and activities of daily living of Parkinson's patients. It also evaluates motor fluctuations, dyskinesias, and autonomic dysfunction. The scale was prepared as 4 parts and 42 items. When the extremities are evaluated separately, it increases up to 55 items. Items are rated from 0 (no symptoms or signs) to 4 (most severe symptoms and signs). The first part evaluates the non- motor features of the disease, such as thoughts, behaviors, and emotions. The second part consists of activities of daily living. In the third part, motor examination, in the fourth part, the complications of the treatment are given. It is used to evaluate the symptoms of the disease and the complications that develop due to treatment. In this scale, which consists of 4 parts, the scoring of each item is between 0-4 points. The increase in the total score reflects the increase in the severity of the symptoms. Baseline
Secondary Modified Hoehn and Yahr Scale This staging scale was developed by Margaret Hoehn and Melvin Yahr (1967) for use in describing the stage of Parkinson's disease. According to the staging scale, the disease is handled in 8 stages. The lower the stage, the better of the stage Parkinson's disease.
Stage 0: No signs of disease Stage 1: Unilateral disease Stage 1.5: Unilateral plus axial involvement. Stage 2: Bilateral disease, no balance disorder. Stage 2.5: Mild bilateral disease recovering on pull test. Stage 3: Mild to moderate bilateral disease and some postural instability, physically independent.
Stage 4: Severe disability, able to stand and walk unaided. Stage 5: Unassisted wheelchair or bed dependent.
Baseline
See also
  Status Clinical Trial Phase
Completed NCT03665493 - Dopamine Effect on Inhibitory Control N/A
Completed NCT02227355 - Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease N/A
Completed NCT01026428 - A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Phase 1/Phase 2
Completed NCT00664157 - Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus N/A
Completed NCT04524143 - The Acute Effect of Cervical Mobilization in Parkinson's Disease N/A
Completed NCT05107531 - Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
Completed NCT04524182 - The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease N/A
Completed NCT00985517 - Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT01968031 - A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Phase 3
Completed NCT01970813 - Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease N/A
Completed NCT01221948 - Vercise Implantable Stimulator for Treating Parkinson's Disease Phase 2
Terminated NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) Phase 3
Completed NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT02240030 - Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Phase 3
Completed NCT00605683 - MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Phase 3
Completed NCT00400634 - Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease Phase 2
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Completed NCT02565628 - PF-06669571 In Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT01617135 - Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Phase 2
Completed NCT01606670 - Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease